Zacks Investment Research upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Several other equities analysts have also recently weighed in on GRFS. BidaskClub cut shares of GRIFOLS S A/S from a sell rating to a strong sell rating in a research note on Friday, July 13th. Morgan Stanley decreased their price target on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an underweight rating for the company in a research note on Monday, October 1st. UBS Group cut shares of GRIFOLS S A/S from a neutral rating to a sell rating in a research note on Wednesday, October 3rd. Berenberg Bank raised shares of GRIFOLS S A/S from a hold rating to a buy rating in a research note on Thursday, October 11th. Finally, Santander raised shares of GRIFOLS S A/S from an underperform rating to a hold rating in a research note on Tuesday, October 30th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $21.50.
Shares of GRFS opened at $21.18 on Wednesday. The company has a market cap of $14.46 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 1.48 and a beta of 1.18. GRIFOLS S A/S has a twelve month low of $17.47 and a twelve month high of $25.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.90 and a quick ratio of 1.12.
Large investors have recently added to or reduced their stakes in the stock. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of GRIFOLS S A/S in the second quarter valued at $6,482,000. Tibra Equities Europe Ltd bought a new position in shares of GRIFOLS S A/S in the second quarter valued at $2,047,000. Citadel Advisors LLC bought a new position in shares of GRIFOLS S A/S in the second quarter valued at $795,000. Van ECK Associates Corp grew its stake in shares of GRIFOLS S A/S by 15.4% in the second quarter. Van ECK Associates Corp now owns 576,179 shares of the biotechnology company’s stock valued at $12,388,000 after buying an additional 77,105 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new position in shares of GRIFOLS S A/S in the second quarter valued at $3,138,000. 21.07% of the stock is owned by institutional investors and hedge funds.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Story: What is a put option?
Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.